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Uterine leiomyoma (UL) or fibroid is the most common estrogen- dependent
tumor of the reproductive system. Almost a quarter of women at reproductive age are
affected with this benign tumor. The purpose of the present study was to investigate the
possible association of IL-1-511and IL-1 3954 polymorphisms with UL in the women
of Charmahal & Bakhtiari province of Iran. Totally, 276 patients with UL and 157 healthy
control women were studied. The genetic polymorphisms for IL-1-511and IL-1 3954
were analyzed by PCR-RFLP method. The results were analyzed with SPSS software using
² test. The TC genotypes of the IL-1 -511C/T polymorphism showed a decreased risk of
UL (OR = 0.232, P = 0.01, 95 % CI = 0.11 – 0.48). A significant difference was found for the
C allele frequencies of the IL-1  -511 C>T polymorphism between the two groups (OR =
0.232, P = 0.01, 95 % CI = 0.11 – 0.48). However, no significant difference was found for
the IL-1 â -3954 polymorphism between the two groups. Our findings indicated that IL-1
â -511C>T promoter polymorphism affects the risk of UL in the women of our study and
this polymorphism might be involved in the pathogens of this disease.
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Uterine leiomyoma (UL) or fibroid is the
most common pelvic benign tumor with a
prevalence of 25% among the women in the
reproductive age and 50% in autopsy report1.
These tumors are the most frequent cause of
hysterectomy and uterine surgery2. UL is the case
in about one third of bedridden cases due to
abnormal uterine bleeding. It is the common reason
of menstrual abnormalities, pelvic pain and other
symptoms which negatively affect the life quality
including infertility, recurrent abortions and
adverse prenatal outcomes1. Despite a wide
research on the factors involved in the initiation
and growth of UL, the main causes of these tumors
remain unknown. The genetic factors underlying
the development and expansion of UL are being
extensively investigated. As to the cause of these
tumors, the hypothesis has been put forth based
on which immunological and inflammatory
processes may play a role3, 4. Possible associations
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of certain cytokine gene polymorphisms with the
the UL have been suggested in numerous
preceding studies5-8. Based on the hypothesis that
cytokines may increase the production of matrix
metalloproteinases, which, in turn, may induce UL
development, the associations of  several single
nucleotide polymorphisms (SNPs) in cytokine
genes and UL have been sought and confirmed9.
Interleukin (IL) - 1 family gene encodes three
homologous polypeptides related together
structurally and functionally10. The IL family gene
is located in a cluster on 2q14 chromosome and
includes two distinct but functionally similar
molecules, IL-1 and IL-1  11 which are produced
by monocytes, macrophages and epithelial cells
during both acute and chronic inflammatory
responses12. It has been shown that a gene in this
cluster is associated with increased production of
IL-1 protein which leads to tissue destruction13, 14.
Several association studies have reported the
association between IL-1 and such diseases as
atherosclerosis, rheumatoid arthritis, peritonitis
and bowel disease15. Two polymorphisms in IL-
1gene, one in the promoter (IL-1-511) and the
other in the coding region (IL-13954) have been
mostly studied. Pietrowski et al. reported a
significant association between IL-1-511 gene
polymorphism and UL development8. Thus, there
is lot of evidence showing the involvement of
genetic determinants in the etiology of UL. The
present study was launched to investigate the
association between the IL-1-511 and IL-13954
gene polymorphisms with UL in a series of Iranian
women.
MATERIALS AND METHODS
Patients and control samples
In this case–control study, we
investigated 276 women with diagnosed UL at the
Department of Gynecology at Shahrekord Hajar
Hospital from 2010 to 2011. UL diagnosis was based
on transvaginal sonographic examination and the
following confirmation by the histological testing
using either myomectomy or hysterectomy. All the
participants were of reproductive age. The control
group also included 157 women without any
evidence of UL, based on the ultrasound exam.
There were no significant differences in age, ethnic
and menarche between the two groups. Cases with
adenomyosis, reproductive tract neoplasm,
pregnancy, ERá dependent cancers, rheumatoid
arthritis and with smoking and alcohol intake habits
were excluded from the study. Informed consent
was obtained from all participants before their
inclusion in the study. All the procedures were
approved by the Ethics Committees of the
Shahrekord University of Medical Sciences. Blood
was taken from all participants and stored at -20°C
until the analyses were carried out.
Genotyping and statistical analysis
Genomic DNA was extracted from EDTA
blood samples by using a standard phenol/
chloroform extraction method. The quality of DNA
was evaluated by spectrophotometer in all samples.
Genotyping of the IL-1-511C>T (promoter) and
IL-1 3954 C>T (exon 5) was performed using the
polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique. The
PCR primers were designed previously8. PCR
primer sequences and restriction anzymes are
shown in Table 1. The 25 µl reaction mix for each
PCR product comprised: 50–100 ng of genomic
DNA, 1.5 µl MgCl2 (50 mM ), 2.5 µl PCR Buffer
(10×), 0.3 µl of each primer (10 pM ), 0.5 µl dNTP(10
mM), 0.1 µl Taq DNA polymerase (5 U/ µl) (Cinagen)
and ddH2O added to  25 µl reactions. PCR
conditions for the amplification of both PCR
products in a Techne TC-412 thermocycler
(Barloworld Scientific, Staffordshire, UK). included
an initial denaturation step at 94°C for 5 min, 34
cycles including 94°C for 30 s, 55°C for 30 s, and
72°C for 45 s and a final extension at 72°C for 7-
min. Digestion of 4 µl of each PCR amplification
product was carried out with 1 U of the specific
restriction enzyme (Fermentas) at 37°C for 16 h
according to manufacturer’s instructions. Both
PCR and digestion products were separated by
vertical non-denaturing 8%polyacrylamide gel and
visualized by silver staining. Expected fragment
lengths of the IL1  -511 polymorphism (AvaI
digested ; heterozygotes (CT)) were 305, 190, and
115 bp, and for the IL1  3954 polymorphism (Taq I
digested; heterozygotes (CT)) were 250, 136, and
114 bp. To confirm the genotyping results, a subset
of PCR-amplified DNA from heterozygous samples
were examined by DNA sequencing, and the results
were 100% concordant. Genotypes and allelic
frequencies for individual polymorphisms were
compared between cases and controls using the
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2 test. P<0.05 was considered statistically
significant. The associations between alleles and
genotype and disease risks were calculated by
odds ratios (OR) with a 95% confidence interval
(CI).
RESULTS
Association between polymorphisms of IL-1 gene
and the risk of UL
The allele and genotype frequencies of
IL-1â-511 and IL-1â3954 in the healthy and UL
groups are shown in Table 2. Patients with UL were
more likely to be homozygous for C allele at position
-511 than the healthy women (19.9% vs 5.7%,
respectively). While, the healthy group showed a
higher frequency of the TC genotype (74.6%
versus 60.2%). Thus, the genotype conferred a
significant protection against UL (OR = 0.232, P =
0.01, 95 % CI = 0.11 – 0.48).
Allele frequencies of the IL1 â 3954
polymorphism were 25% and 26% for the T allele
and 75% and 74% for the C allele in patients and
controls, respectively (P > 0.05). Thus, there were
no significant differences in IL1 â 3954 genotype
or allele frequencies between women with UL and
controls.
DISCUSSION
In the current study, we investigated the
association of two polymorphisms in IL-1-511C>T
(promoter) and IL-1  3954 C>T (exon 5) gene with
UL in 276 patient compared to157 normal women
as the control group. Studies have shown that
polymorphism in various cytokines cause
Table 1. Primer sequences for IL-1â-511 promoter, IL-1â 3953 exon 5
SNP Location Primer sequence DNA fragment Restriction
Size (bp) Anzymes
IL-1â-511C>T promoter F 5´-TGG CAT TGA TCT GGT TCA TC-3´ TT 305 AvaI
R 5´-GTT TAG GAA TTC TCC CAC TT-3 CT 190 +115 + 305
CC190 + 115
IL-1â3954C>T Exon5 F5´-GTT GTC ATC AGA CTT TGA CC-3´ TT250 TaqI
R 5´-TTC AGT TCA TAT GGA CCA GA-3 CT136 + 114 + 250
CC136 + 114
Table 2. Genotype and allele frequencies
IL-1 Myoma(276 ) Control(157) OR (95% CI) P-value
â -511 AvaI No.(%) No.(%)
Genotypes
CC 55(19.9) 9(5.7) 1.00
CT 166(60.2) 117(74.6) 0.232(0.11- 0.48) 0.01
TT 55(19.9) 31(19.7) 0.290(0.57 -0.99) 0.03
Alleles
C 276(0.5) 135(0.43) 1.00(ref0
T 276(0.5) 179(0.57) 0.754(0.57 – 0.99) 0.04
IL-1 Myoma(276 ) Control(157)      OR (95% CI) P-value
â 3954TaqI No.(%) No.(%)
Genotypes
CC 158(57.2) 87(55.4) 1.00
CT 98(37.6) 59(35.5) 0.915(0.60 – 0.38) 0.674
TT 20(7.3) 11(7) 1.001(0.45 – 2.18) 0.998
Alleles
138(0.25) 81(0.26) 1.00(ref)
CT 414(0.75) 233(0.74 0.959(0.69 – 0.31) 0.796
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susceptibility to some diseases16, 17. Polymorphisms
in the regulatory region of a cytokine gene can
alter its expression level related to immunologic
reactions18, 19. It seems that the susceptibility genes
interact both with other genes and peripheral
factors to accelerate the disease development20, 21.
Studies have shown that interleukins and other
cytokines may be involved in susceptibility to
develop various gynecological neoplasms7, 22, 23.
Because IL-1b may exert a detrimental effect on
leiomyoma development, we hypothesize that its
gene polymorphisms may be associated with the
pathogenesis of UL. In this study, IL-1B -511 TC
heterozygotes were significantly lower in the
patient group, suggesting that the -511TC
genotypes might have a protective effect in the
development of UL (OR = 0.232, P = 0.01, 95 % CI =
0.11 – 0.48). Also, we found that women
homozygous for the -511CC genotype had a greater
risk of UL.
This is the first study in the Iranian
population to show a specific genotype of the IL-
1B at -511TC is protective against UL. Studies have
demonstrated the increased production of IL-1b
when the T allele is present at IL-1b-51124, 25. We
could infer that the CC (-511) genotype in the
promoter region is associated with reduced IL-1b
levels of the proinflammatory signals in response
to stimulation. This is consistent with the findings
of  other studies on Asian women8. Our finding is
also consistent with the results of Pietrowski and
coworkers8. Interplay between IL-1-511genotypes
and some peripheral factors might underlie the
discrepancies found among studied populations.
It is well possible that IL-1 gene polymorphism
affects the susceptibility to UL in those
populations which are exposed to specified
peripheral factors. A meta-analysis on the
associations of Interleukin-1beta and interleukin-
1 receptor antagonist gene polymorphisms and
gastric cancer has confirmed these differential
effects observed between two Caucasian and
Asian populations26.
In our study, no differences were found
in either genotype or allele frequencies of the IL-
13954C D T polymorphism between patient and
control groups. The result of the present study
corresponded well with those of other studies on
the IL-13954C/T   polymorphism and the risk of
UL. In study that carried out by Hsieh et al. in
Taiwan, no association was found between IL-
13954 gene polymorphism and UL6. Likewise,
Pietrowski et al. did not find any association
between IL-13954C/T gene polymorphism and
UL8. This study has been conducted with a larger
sample size to confirm our previose report27.
In summary, the obtained result from this
study indicated that Iranian patients with IL-1b-
511 CC genotype have an increased risk of
leiomyoma. Interestingly, we also found that the
IL-1b-511CT genotype had a protective effect on
the development of UL in our study population.
Therefore, this SNP could serve as a useful marker,
together with other risk factors, to predict the
susceptibility to UL. Further studies are needed to
clarify the exact role of the IL-1 gene
polymorphism in the pathogenesis of UL.
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